|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ischemic cholangiopathy after livertransplantation显示文摘Orthotopic liver transplantation ( OLT) has evolved over the last forty years from an experimental endeavor to standard of care therapy for many patients with end stage hepatic disease. Many technical advances have contributed to the current success of OLT, but surgical complications, especially involving the biliary reconstruction, remain a morbid problem. Biliary complications after OLT include leaks and strictures. Strictures may be anastoinotic or intrahepatic and diffuse, as seen in cases of hepatic artery thrombosis. Current efforts to expand the limited donor pool include the use of non-heart beating donors. The organ procurement process in these donors entails an increased period of warm ischemia and results with non-heart beating donor grafts have been mixed. It is now appreciated that there is an increased incidence of subsequent diffuse biliary stricturing or ' ischemic cholangiopathy' in recipients of these organs. Animal models of this phenomenon and potential therapeutic strategies targeted at ischemic cholangiopathy are being developed with potential applicability to non-heart beating donation and will be the focus of this review. | Andrew M. Cameron Ronald W. Busuttil | 2005 | Hepatobiliary & Pancreatic Diseases International2005，4，4： | 22 |
| 2 | Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome显示文摘Hepatocellular carcinoma(HCC) remains a common and lethal malignancy worldwide and arises in the setting of a host of diseases. The incidence continues to increase despite multiple vaccines and therapies for viruses such as the hepatitis B and C viruses. In addition, due to the growing incidence of obesity in Western society, there is anticipation that there will be a growing population with HCC due to non-alcoholic fatty liver disease. Due to the growing frequency of this disease, screening is recommended using ultrasound with further imaging using magnetic resonance imaging and multi-detector computed tomography used for further characterization of masses. Great advances have been made to help with the early diagnosis of small lesions leading to potential curative resection or transplantation. Resection and transplantation maybe used in a variety of patients that are carefully selected based on underlying liver disease. Using certain guidelines and clinical acumen patients may have good outcomes with either resection or transplantation however many patients are inoperable at time of presentation. Fortunately, the use of new locoregional therapies has made down staging patients a potential option making them potential surgical candidates. Despite a growing population with HCC, new advances in viral therapies, chemotherapeutics, and an expanding population of surgical and transplant candidates might all contribute to improved long-term survival of these patients. | Adam S Bodzin Ronald W Busuttil | 2015 | World Journal of Hepatology2015，7，9： | 22 |
| 3 | Liver transplantation for hepatocellular carcinoma: the Hangzhou experience显示文摘Over the last 25 years orthotopic liver transplantation (OLT) has been proven a durabletherapy for all forms of end stage | Ronald W. Busuttil | 2008 | Hepatobiliary & Pancreatic Diseases International2008，7，3： | 12 |
| 4 | Liver transplantation for hepatocellular carcinoma:an update显示文摘BACKGROUND: Hepatocellular carcinoma (HCC) is a heterogeneous malignancy with multiple etiologies, high incidence, and high mortality. The standard surgical management for patients with HCC consists of locoregional ablation, surgical resection, or liver transplantation, depending on the background state of the liver. Eighty percent of patients initially presenting with HCC are unresectable, either due to the extent of tumor or the level of underlying hepatic dysfunction. While in patients with no evidence of cirrhosis and good hepatic function resection has been the surgical treatment of choice, it is contraindicated in patients with moderate to severe cirrhosis. Liver transplantation is the optimal surgical treatment. DATA SOURCES: PubMed search of recent articles (from January 2000 to March 2011) was performed looking for relevant articles about hepatocellular carcinoma and its treatment. Additional articles were identified by evaluating references from selected articles. RESULTS: Here we review criteria for transplantation, the types, indications, and role of locoregional therapy in treating the cancer and in downstaging for possible later transplantation. We also summarize the contribution of immunosuppression and adjuvant chemotherapy in the management and prevention of HCC recurrence. Finally we discuss recent advances in imaging, tumor biology, and genomics as we delineate the remaining challenges for the diagnosis and treatment of this disease. CONCLUSIONS: Much can be improved in the diagnosis and treatment of HCC. A great challenge will be to improve patient selection to criteria based on tumor biology. Another will be to incorporate systemic agents post-operatively in patients at high risk for recurrence, paying close attention to efficacy and safety. The future direction of the effort in treating HCC will be to stimulate prospective trials, develop molecular imaging of lymphovascular invasion, to improve recipient selection, and to investigate biomarkers of tumor biology. | Ali Zarrinpar Fady Kaldas Ronald W Busuttil | 2011 | Hepatobiliary & Pancreatic Diseases International2011，10，3： | 8 |
| 5 | Nationwide trends and predictors of inpatient mortality in 83884 transjugular intrahepatic portosystemic shunt显示文摘AIM: To evaluate and validate the national trends and predictors of in-patient mortality of transjugular intrahepatic portosystemic shunt(TIPS) in 15 years.METHODS: Using the National Inpatient Sample which is a part of Health Cost and Utilization Project, we identified a discharge-weighted national estimate of 83884 TIPS procedures performed in the United States from 1998 to 2012 using international classification of diseases-9 procedural code 39.1. The demographic, hospital and co-morbility data were analyzed using a multivariant analysis. Using multi-nominal logistic regression analysis, we determined predictive factors related to increases in-hospital mortality. Comorbidity measures are in accordance to the Comorbidity Software designed by the Agency for Healthcare Research and Quality.RESULTS: Overall, 12.3% of patients died during hospitalization with downward trend in-hospitalmortality with the mean length of stay of 10.8 ± 13.1 d. Notable, African American patients(OR = 1.809 vs Caucasian patients, P < 0.001), transferred patients(OR = 1.347 vs non-transferred, P < 0.001), emergency admissions(OR = 3.032 vs elective cases, P < 0.001), patients in the Northeast region(OR = 1.449 vs West, P < 0.001) had significantly higher odds of inhospital mortality. Number of diagnoses and number of procedures showed positive correlations with in-hospital death(OR = 1.249 per one increase in number of procedures). Patients diagnosed with acute respiratory failure(OR = 8.246), acute kidney failure(OR = 4.359), hepatic encephalopathy(OR = 2.217) and esophageal variceal bleeding(OR = 2.187) were at considerably higher odds of in-hospital death compared with ascites(OR = 0.136, P < 0.001). Comorbidity measures with the highest odds of in-hospital death were fluid and electrolyte disorders(OR = 2.823), coagulopathy(OR = 2.016), and lymphoma(OR = 1.842).CONCLUSION: The overall mortality of the TIPS procedure is steadily decreasing, though the length of stay has remained relatively constant. Specific patient ethnicity, location, transfer status, primary diagnosis and comorbidities correlate with increased odds of TIPS in-hospital death. | Edward Wolfgang Lee Andrew Kuei Sammy Saab Ronald W Busuttil Francisco Durazo Steven-Huy Han Mohamed M El-Kabany Justin P Mc Williams Stephen T Kee | 2016 | World Journal of Gastroenterology2016，22，25： | 7 |
| 6 | Immunological battlefield in gastric cancer and role of immunotherapies显示文摘Like the wars predating the First World War where human foot soldiers were deemed tools in the battlefield against an enemy, so too are the host immune cells of a patient battling a malignant gastric cancer. Indeed, the tumour microenvironment resembles a battlefield, where the patient's immune cells are the defence against invading tumour cells. However, the relationship between different immune components of the host response to cancer is more complex than an 'us against them' model. Components of the immune system inadvertently work against the interests of the host and become pro-tumourigenic while other components soldier on against the common enemy – the tumour cell. | Minyu Wang Rita A Busuttil Sharon Pattison Paul J Neeson Alex Boussioutas | 2016 | World Journal of Gastroenterology2016，22，28： | 4 |
| 7 | Liver Transplantation Criteria For Hepatocellular Carcinoma Should Be Expanded: A 22-Year Experience With 467 Patients at UCLA显示文摘 | John P. Duffy Andrew Vardanian Elizabeth Benjamin Melissa Watson Douglas G. Farmer Rafik M. Ghobrial Gerald Lipshutz Hasan Yersiz David S. K. Lu Charles Lassman Myron J. Tong Jonathan R. Hiatt Ronald W. Busuttil | 2007 | Annals of Surgery2007，，3： | 3 |
| 8 | Dangerous dietary supplements: Garcinia cambogia-associated hepatic failure requiring transplantation显示文摘Commercial dietary supplements are marketed as a panacea for the morbidly obese seeking sustainable weight-loss. Unfortunately, many claims cited by supplements are unsupported and inadequately regulated. Most concerning, how ever, are the associated harmful side effects, often unrecognized by consumers. Garcinia cambogia extract and Garcinia cambogia containing products are some of the most popular dietary supplements currently marketed for weight loss. Here, we report the first known case of fulminant hepatic failure associated with this dietary supplement. One active ingredient in this supplement is hydroxycitric acid, an active ingredient also found in weight-loss supplements banned by the Food and Drug Administration in 2009 for hepatotoxicity. Heightened awareness of the dangers of dietary supplements such as Garcinia cambogia is imperative to prevent hepatoxicity and potential fulminant hepatic failure in additional patients. | Keri E Lunsford Adam S Bodzin Diego C Reino Hanlin L Wang Ronald W Busuttil | 2016 | World Journal of Gastroenterology2016，22，45： | 3 |
| 9 | Vascular Complications of Orthotopic Liver Transplantation: Experience in More than 4,200 Patients显示文摘 | John P. Duffy Johnny C. Hong Douglas G. Farmer Rafik M. Ghobrial Hasan Yersiz Jonathan R. Hiatt Ronald W. Busuttil | 2009 | Journal of the American College of Surgeons2009，，5： | 3 |
| 10 | Long-Term Patient Outcome and Quality of Life After Liver Transplantation: Analysis of 20-Year Survivors显示文摘 | John P. Duffy Kenneth Kao Clifford Y. Ko Douglas G. Farmer Sue V. McDiarmid Johnny C. Hong Robert S. Venick Susan Feist Leonard Goldstein Sammy Saab Jonathan R. Hiatt Ronald W. Busuttil | 2010 | Annals of Surgery2010，，4： | 3 |
| 11 | Liver Transplantation in Highest Acuity Recipients: Identifying Factors to Avoid Futility显示文摘 | Henrik Petrowsky Abbas Rana Fady M. Kaldas Anuj Sharma Johnny C. Hong Vatche G. Agopian Francisco Durazo Henry Honda Jeffrey Gornbein Victor Wu Douglas G. Farmer Jonathan R. Hiatt Ronald W. Busuttil | 2014 | Annals of Surgery2014，，6： | 2 |
| 12 | Liver Transplantation for Nonalcoholic Steatohepatitis: The New Epidemic显示文摘 | Vatche G. Agopian Fady M. Kaldas Johnny C. Hong Meredith Whittaker Curtis Holt Abbas Rana Ali Zarrinpar Henrik Petrowsky Douglas Farmer Hasan Yersiz Victor Xia Jonathan R. Hiatt Ronald W. Busuttil | 2012 | Annals of Surgery2012，，4： | 2 |
| 13 | Chronic Viral Hepatitis and Hepatocellular Carcinoma显示文摘 | Yagil Barazani Jonathan R. Hiatt Myron J. Tong Ronald W. Busuttil | 2007 | World Journal of Surgery2007，，6： | 2 |
| 14 | Pretransplant Model to Predict Posttransplant Survival in Liver Transplant Patients显示文摘 | Rafik M. Ghobrial Jeffery Gornbein Randy Steadman Natale Danino James F. Markmann Curtis Holt Dean Anselmo Farin Amersi Pauline Chen Douglas G. Farmer Steve Han Francisco Derazo Sammy Saab Leonard I. Goldstein Sue V. McDiarmid Ronald W. Busuttil | 2002 | Annals of Surgery2002，，3： | 2 |
| 15 | Hepatocellular carcinoma screening in patients waiting for liver transplantation: A decision analytic model显示文摘 | Sammy Saab David Ly Jose Nieto Fasiha Kanwal David Lu Steven Raman Rafael Amado Barbara Nuesse Francisco Durazo Steven Han Douglas G. Farmer Rafik M. Ghobrial Hasan Yersiz Pauline Chen Kathy Schwegel Leonard I. Goldstein Myron Tong Ronald W. Busuttil | 2003 | Liver Transplantation2003，，7： | 2 |
| 16 | Liver Transplantation for Nonalcoholic Steatohepatitis: The New Epidemic显示文摘 | Vatche G. Agopian Fady M. Kaldas Johnny C. Hong Meredith Whittaker Curtis Holt Abbas Rana Ali Zarrinpar Henrik Petrowsky Douglas Farmer Hasan Yersiz Victor Xia Jonathan R. Hiatt Ronald W. Busuttil | 2012 | Annals of Surgery2012，，4： | 2 |
| 17 | Interleukin-22: Implications for Liver Ischemia-Reperfusion Injury显示文摘 | Paul J. Chestovich Yoichiro Uchida William Chang Mark Ajalat Charles Lassman Robert Sabat Ronald W. Busuttil Jerzy W. Kupiec-Weglinski | 2012 | Transplantation2012，，5： | 2 |
| 18 | Analysis of Long-term Outcomes of 3200 Liver Transplantations Over Two Decades: A Single-Center Experience显示文摘 | Ronald W. Busuttil Douglas G. Farmer Hasan Yersiz Jonathan R. Hiatt Sue V. McDiarmid Leonard I. Goldstein Sammy Saab Steven Han Francisco Durazo Michael Weaver Carlos Cao Tony Chen Gerald S. Lipshutz Curtis Holt Sherilyn Gordon Jeffery Gornbein Farin Amer | 2005 | Annals of Surgery2005，，6： | 2 |
| 19 | Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically显示文摘 | Tracy L. Putoczki Stefan Thiem Andrea Loving Rita A. Busuttil Nicholas J. Wilson Paul K. Ziegler Paul Nguyen Adele Preaudet Ryan Farid Kirsten Edwards Yeliz Boglev Rodney B. Luwor Andrew Jarnicki David Horst Alex Boussioutas Joan K. Heath Oliver M. Sieber | 2013 | Cancer Cell2013，，： | 2 |
| 20 | A model to predict the development of mental status changes of unclear cause after liver transplantation显示文摘 | Fasiha Kanwal David Chen Lena Ting Jeffrey Gornbein Sammy Saab Francisco Durazo Hasan Yersiz Douglas Farmer R. Mark Ghobrial Ronald W. Busuttil Steven-Huy Han | 2003 | Liver Transplantation2003，，12： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员